Core Viewpoint - The market anticipates West Pharmaceutical Services (WST) to report a year-over-year earnings increase driven by higher revenues in its upcoming earnings report for the quarter ended December 2025 [1] Group 1: Earnings Expectations - The consensus estimate for quarterly earnings is $1.83 per share, reflecting a year-over-year change of +0.6% [3] - Expected revenues are projected at $794.26 million, which is a 6.1% increase from the same quarter last year [3] Group 2: Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - West Pharmaceutical's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.78%, suggesting a bearish sentiment among analysts [11] Group 3: Historical Performance - In the last reported quarter, West Pharmaceutical exceeded the expected earnings of $1.67 per share by delivering $1.96, resulting in a surprise of +17.37% [12] - The company has beaten consensus EPS estimates in all four of the last quarters [13] Group 4: Market Sentiment and Stock Movement - The stock may experience upward movement if the upcoming earnings report exceeds expectations, while a miss could lead to a decline [2] - Despite a potential earnings beat, other factors may influence stock performance, making it essential to consider broader market conditions [14][16]
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?